Literature DB >> 4014311

The effect of Mendelian disease on human health. II: Response to treatment.

A Hayes, T Costa, C R Scriver, B Childs.   

Abstract

We describe an attempt to measure efficacy of treatment in the Mendelian diseases of man. We used the McKusick Catalogs to identify 351 single gene diseases. We scored the impact of each disease in seven phenotypic categories: lifespan, reproductive capability, somatic growth, intellectual development, learning ability, capacity to work, and cosmetic effect. We then scored the success of treatment in ameliorating each of these component manifestations separately and together. The response to treatment was slight in the whole sample (n = 351): lifespan was increased in 15%, reproductive capability in 11%, and social adaptation in 6%. We observed that the mutant gene product was known in only 15% of the conditions comprising our sample. Since the mutant polypeptide is known in most inborn errors of metabolism, the diseases of this type (n = 65) in our sample of Mendelian traits were studied separately. In each of the seven categories of phenotypic impact, only a few of the hereditary metabolic diseases responded in any degree to specific treatment: the treatment gave complete relief in 12%, there was a partial response in 40%, and none in the remaining 48%. These findings have implications for prognosis, genetic counseling, and medical care of patients with Mendelian disease.

Entities:  

Mesh:

Year:  1985        PMID: 4014311     DOI: 10.1002/ajmg.1320210206

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

1.  2001 ASHG Award for Excellence in Education. Introductory speech for Charles Scriver.

Authors:  David Valle
Journal:  Am J Hum Genet       Date:  2002-01-04       Impact factor: 11.025

2.  Changing paternal age distribution and the human mutation rate in Europe.

Authors:  B Modell; A Kuliev
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

Review 3.  Genetic screening, testing and treatment: how far can we go?

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

4.  Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.

Authors:  E Treacy; C L Clow; T R Reade; D Chitayat; O A Mamer; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

5.  Physiological genetics--who needs it?

Authors:  C R Scriver
Journal:  Am J Hum Genet       Date:  1987-03       Impact factor: 11.025

Review 6.  Does hereditary metabolic disease modulate senescence and ageing?

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

Review 7.  Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison.

Authors:  E Treacy; B Childs; C R Scriver
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

Review 8.  Fertility, reproduction, and genetic disease: studies on the mutagenic effects of environmental agents on mammalian germ cells.

Authors:  M D Shelby; J B Bishop; J M Mason; K R Tindall
Journal:  Environ Health Perspect       Date:  1993-04       Impact factor: 9.031

9.  Whole-exome sequencing improves genetic testing accuracy in pulmonary artery hypertension.

Authors:  Xiaofang Zeng; Tianyu Lian; Jianhui Lin; Suqi Li; Haikuo Zheng; Chunyan Cheng; Jue Ye; Zhicheng Jing; Xiaojian Wang; Wei Huang
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.